Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.

Methotrexate polyglutamates (MTXPGs) determine in vivo efficacy in acute lymphoblastic leukemia (ALL). MTXPG accumulation differs by leukemic subtypes, but genomic determinants of MTXPG variation in ALL remain unclear. We analyzed 3 types of whole genome variation: leukemia cell gene expression and somatic copy number variation, and inherited single nucleotide polymorphism (SNP) genotypes and determined their association with MTXPGs in leukemia cells. Seven genes (FHOD3, IMPA2, ME2, RASSF4, SLC39A6, SMAD2, and SMAD4) displayed all 3 types of genomic variation associated with MTXPGs (P < .05 for gene expression, P < .01 for copy number variation and SNPs): 6 on chromosome 18 and 1 on chromosome 10. Increased chromosome 18 (P = .002) or 10 (P = .036) copy number was associated with MTXPGs even after adjusting for ALL subtype. The expression of the top 7 genes in leukemia cells accounted for more variation in MTXPGs (46%) than did the expression of the top 7 genes in normal HapMap cell lines (20%). The top 7 inherited SNPs in patients accounted for approximately the same degree of variation (17%) in MTXPGs as did the top 7 SNP genotypes in HapMap cell lines (20%). We conclude that acquired genetic variation in leukemia cells has a stronger influence on MTXPG accumulation than inherited genetic variation.

[1]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[2]  W. Evans,et al.  Cancer Pharmacogenomics May Require Both Qualitative and Quantitative Approaches , 2005, Cell cycle.

[3]  L. Matherly,et al.  In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells. , 1983, Cancer research.

[4]  A. Borkhardt,et al.  Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. , 1996, Leukemia.

[5]  J. Downing,et al.  Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.

[6]  M. Greaves,et al.  Origins of chromosome translocations in childhood leukaemia , 2003, Nature Reviews Cancer.

[7]  J. Marcelletti,et al.  HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. , 2003, Clinical chemistry.

[8]  F. Behm,et al.  Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. , 1996, Leukemia.

[9]  J. Downing,et al.  Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. , 2005, The Journal of clinical investigation.

[10]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[11]  Cheng Li,et al.  dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data , 2004, Bioinform..

[12]  M. Relling,et al.  Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia , 1994 .

[13]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[14]  A. Look,et al.  Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. , 1992, Blood.

[15]  Stark Am.  Letter: Screening for breast cancer. , 1976 .

[16]  G. Peters,et al.  Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  M. Relling,et al.  Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up‐front treatment of acute lymphoblastic leukemia , 2003, Clinical pharmacology and therapeutics.

[18]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[19]  Carl W. Miller,et al.  Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. , 2007, Blood.

[20]  G. Janka‐Schaub,et al.  Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92 , 2000, Leukemia.

[21]  S. Raimondi,et al.  Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. , 1999, Blood.

[22]  W. Hiddemann,et al.  Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.

[23]  Christopher B. Miller,et al.  BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.

[24]  N. Winick,et al.  Analysis of methotrexate polyglutamate derivatives in vivo. , 1986, Methods in enzymology.

[25]  Sue Goo Rhee,et al.  Peroxiredoxin III, a Mitochondrion-specific Peroxidase, Regulates Apoptotic Signaling by Mitochondria* , 2004, Journal of Biological Chemistry.

[26]  C. Pui,et al.  Biology and treatment of acute lymphoblastic leukemia , 1994 .

[27]  Ching-Hon Pui,et al.  A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia , 2002, Cancer Chemotherapy and Pharmacology.

[28]  A. Look,et al.  The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study , 2001, Leukemia.

[29]  T. Kute,et al.  Proliferation-dependent cytotoxicity of methotrexate in murine L5178Y leukemia. , 1988, Cancer research.

[30]  M. Amylon,et al.  Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. , 1997, Blood.

[31]  C. Ragan,et al.  The purification and properties of myo-inositol monophosphatase from bovine brain. , 1988, The Biochemical journal.

[32]  Cheng Cheng,et al.  In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile , 2008, PLoS medicine.

[33]  S. Raimondi,et al.  Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia , 2007, Genes, chromosomes & cancer.

[34]  M. Relling,et al.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. , 1996, The Journal of clinical investigation.

[35]  A. Biggeri,et al.  Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer. , 2007, Oncology research.

[36]  References , 1971 .

[37]  A. Look,et al.  Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. , 1998, Leukemia & lymphoma.

[38]  M. Eileen Dolan,et al.  A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity , 2007, Proceedings of the National Academy of Sciences.

[39]  S L George,et al.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. , 1986, The New England journal of medicine.

[40]  M. Relling,et al.  Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. , 1994, Blood.

[41]  D. Neuberg,et al.  Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. , 2007, Blood.

[42]  M. Relling,et al.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. , 1994, The Journal of clinical investigation.

[43]  M. Loh,et al.  Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). , 2007, Blood.

[44]  J. Downing,et al.  Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.

[45]  W. Bowman,et al.  METHOTREXATE SYSTEMIC CLEARANCE INFLUENCES PROBABILITY OF RELAPSE IN CHILDREN WITH STANDARD-RISK ACUTE LYMPHOCYTIC LEUKAEMIA , 1984, The Lancet.

[46]  S. Raimondi,et al.  Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes , 2005, Nature Genetics.

[47]  J. Galivan.  Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. , 1980, Molecular pharmacology.

[48]  M. Mazumdar,et al.  Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. , 1997, Blood.

[49]  Chi V. Dang,et al.  The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  S. Richards,et al.  Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. , 2003, Blood.

[51]  J. Downing,et al.  Concordant Gene Expression in Leukemia Cells and Normal Leukocytes Is Associated with Germline cis-SNPs , 2008, PloS one.

[52]  F. Behm,et al.  Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. , 2003, Blood.

[53]  M. Relling,et al.  Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. , 1997, Molecular pharmacology.

[54]  Christian Urban,et al.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. , 2007, Blood.

[55]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[56]  M. Stolte,et al.  Clonal relationship in multifocal non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue (MALT) , 2004, Annals of Hematology.

[57]  J. Harbott,et al.  Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. , 2004, Blood.

[58]  C. Pui,et al.  Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.

[59]  E. Lander,et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.

[60]  M. Relling,et al.  Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia. , 2009, NCI monographs : a publication of the National Cancer Institute.

[61]  S. Raimondi,et al.  Cytogenetics as a Diagnostic Aid for Childhood Hematologic Disorders , 1998 .

[62]  W. Bleyer,et al.  Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995 , 2000, Leukemia.